Address : 3rd floor, B Building, 33, Gwacheon-daero 7-gil, Gwacheon-si, Gyeonggi-do, Republic of Korea
General : firstname.lastname@example.orgIR : email@example.comMedia : firstname.lastname@example.org
Read latest news from Bertis
Bertis to Present 10 Research Outcomes at HUPO 2023, Including Development of Next-generation Analysis Method for Proteomic Data
Including Development of Next-generation Analysis Method for Proteomic Data
- HUPO, one of the world's largest proteomics societies, is returning to Korea for the first time in 16 years to be held at BEXCO, Busan from September 17 to 21
- Bertis joins as a major sponsor in the event which attracts over 1,000 scholars and key industry officials from 40 countries
- Bertis presents 10 studies, including the development of next-generation mass spectrometry and single-cell proteomic analysis, and highlights its core technology framework, ‘ProteoID’, as well as nine essential technologies
Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced on September 7 that it would participate in ‘2023 HUPO, Human Proteome Organization’, one of the largest international academic gatherings in the field of proteomics. The event will take place from September 17 to 21 in Busan, Korea.
HUPO 2023, themed 'Together Through Proteomics,' is scheduled to be held at BEXCO in Busan. The event is expected to draw over 1,000 researchers and prominent figures from more than 40 countries. This annual event, inaugurated in France in 2002, has been held continuously, rotating through the Americas, Asia, Oceania, Europe, and Africa. It now returns to Korea after 16 years since its last appearance in Seoul in 2007
During the event, Bertis will deliver presentations on 10 studies, including the development of next-generation mass spectrometry and single-cell proteomic analysis methodologies. The three main topics Bertis will cover in oral presentations are ▲ Broad Target Scanning (BTS) - a pragmatic LC-MS acquisition method for collecting population-scale real-world proteomics data ▲ Identification of Secreted Unannotated Small ORF Microproteins from Adipocytes and in Plasma to Elucidate Function of Novel Gene Product Proteins ▲ Spatial proteomic approaches for triple-negative breast cancer on single-cell resolution. In addition, the company will provide seven poster presentations on DeepMRM: Deep learning-based object detection model for proteomics data, Exploring the Human Aging Blood Proteome, and others.
<Image> List of Bertis’ oral presentations to be delivered at HUPO 2023
(See the overview of presentation details below)
Seung-man Han, CEO of Bertis, said, “It is encouraging for the Korean proteomics industry and academia that the representative academic event in the proteomics field is held in Korea at this critical juncture when the use cases of proteomics technology are rapidly increasing across all areas of the bio industry. Bertis will also leverage the upcoming HUPO 2023 as an opportunity to introduce Korea's technologies to the global proteomics community and make its utmost efforts to contribute to substantial breakthroughs in the development of proteomics technology.
Bertis plans to focus on promoting protein data analysis and interpretation capabilities, as well as know-how in technological commercialization through HUPO 2023. The company will set up a large promotional booth inside the conference hall to introduce nine core technologies related to biomarker discovery and algorithm development, diagnostic service commercialization, and advanced technology. The primary focus will be on the core technology framework ‘ProteoID(Proteome Integrated Determination)’. Furthermore, it will publicize its pipeline of multi-marker solutions for early diagnosis, including ‘MASTOCHECK®’, an early diagnosis blood test for breast cancer, and PASS (Pan-omics Analysis Service & Solution).
<Image> ProteoID, Bertis’ core technology system, and nine essential technologies
The name ProteoID is derived from the term 'proteoid roots,' which refers to the densely packed roots of plants. It implies the interactions among proteins, combinations of various disease markers, and the organic blend of proteomics technologies. Bertis is fully committed to realizing the potential of proteomics in clinical and medical contexts based on ProteoID, a technology system that encompasses all stages of utilizing proteomics technology, from protein data analysis to product and service commercialization.